Rocket Pharmaceuticals: First Approval and Extended Cash Runway Offset by Long Path to Meaningful Kresladi Revenues, Warranting a Hold Rating

Needham analyst Gil Blum has maintained their neutral stance on RCKT stock, giving a Hold rating on March 25.

Gil Blum has given his Hold rating due to a combination of factors related to both the opportunity and the remaining uncertainties around Rocket Pharmaceuticals. The recent accelerated approval of Kresladi for severe LAD-I marks the company’s first commercial product and brings with it a valuable Priority Review Voucher, which management plans to sell to extend the cash runway from year-end 2025 into early 2028, reducing near-term financing risk.

The commercial impact, however, is still several years away, as Kresladi is not expected to launch until the fourth quarter of 2026, with revenue contributions beginning in the first half of 2027, and pricing has yet to be disclosed beyond guidance that it will align with industry norms. While Phase II data show strong survival and safety outcomes and full approval will rely on further follow-up rather than a new trial, the long lead time to meaningful revenue and remaining execution risk support a more cautious, neutral stance at this stage rather than a more aggressive rating.

In another report released on March 25, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $4.00 price target.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCKT in relation to earlier this year.